Oppenheimer raised the firm’s price target on MannKind (MNKD) to $15 from $12 and keeps an Outperform rating on the shares. The firm is updating its model to include TYVASO DPI royalties following positive Phase 3 results from TETON-2 in IPF and FUROSCIX following the acquisition of scPharma. Oppenheimer sees TYVASO becoming a backbone therapy in IPF generating about $5.4B in sales in 2033 and subsequently enhancing MannKind’s DPI royalty stream.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- Positive TETON-2 Study Results Drive Buy Rating and Price Target Increase for MannKind
- MannKind price target raised to $11 from $9 at H.C. Wainwright
- Unusually active option classes on open September 2nd
- MannKind’s Strategic Collaborations and Innovations Drive Buy Rating Amid Promising IPF Treatment Developments
- Marvell downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls